36
Participants
Start Date
May 8, 2019
Primary Completion Date
August 4, 2019
Study Completion Date
Tucatinib
Administered via oral tablet
PAREXEL International, Early Phase Clinical Unit - Los Angeles, Glendale
Seagen Inc.
INDUSTRY